Table 1 Open in new tab Baseline...

	All patients	Limited ablation group	Extended ablation group	P
Age (years)	71 (61; 75)	70 (61; 75)	71 (60; 74)	NS
Males	41 (55%)	24 (63%)	17 (47%)	NS
Aetiology of PH
– Idiopathic	41 (55%)	23 (61%)	18 (50%)	NS
– Chronic thromboembolic	22 (30%)	10 (26%)	12 (33%)	NS
– Lung disease/hypoxia	11 (15%)	5 (13%)	6 (17%)	NS
Index arrhythmia
– Atrial fibrillation	38 (51%)	19 (50%)	19 (53%)	NS
– Paroxysmal	11 (15%)	6 (16%)	5 (14%)	NS
– Persistent	22 (30%)	10 (26%)	12 (33%)	NS
– Long-standing persistent	5 (7%)	3 (8%)	2 (6%)	NS
– Atrial tachycardia	36 (49%)	19 (50%)	17 (47%)	NS
– Typical atrial flutter	23 (31%)	12 (32%)	11 (31%)	NS
Symptoms of arrhythmia
– Palpitation	28 (38%)	13 (34%)	15 (42%)	NS
– Dyspnea	47 (64%)	24 (63%)	23 (64%)	NS
– Peripheral oedema	26 (35%)	12 (32%)	14 (39%)	NS
Comorbidities
– Arterial hypertension	59 (80%)	31 (82%)	28 (78%)	NS
– Diabetes mellitus	26 (35%)	12 (32%)	14 (39%)	NS
– Coronary artery disease	14 (19%)	5 (13%)	9 (25%)	NS
– Stroke/transient ischaemic attack	6 (8%)	4 (11%)	2 (6%)	NS
CHA₂DS₂-VASc score	3 (2; 4)	3 (2; 4)	3 (2; 4)	NS
HAS-BLED score	1 (0; 1)	1 (0; 1)	1 (0.5; 1)	NS
Treatment
– Amiodarone	14 (19%)	8 (21%)	6 (17%)	NS
– Propafenone	3 (4%)	2 (5%)	1 (3%)	NS
– Sotalol	2 (3%)	1 (3%)	1 (3%)	NS
– Beta-blockers	27 (36%)	13 (34%)	14 (38%)	NS
– Warfarin	37 (50%)	18 (47%)	19 (53%)	NS
– Direct oral anticoagulants	31 (42%)	18 (47%)	13 (36%)	NS
– Specific therapy for PH	26 (35%)	14 (37%)	12 (33%)	NS
Functional status
– NYHA I	0	0	0	NS
– NYHA II	17 (23%)	9 (24%)	8 (22%)	NS
– NYHA III	57 (77%)	29 (76%)	28 (78%)	NS
– NYHA IV	0	0	0	NS
– 6-minute walking test (m)	369 (280; 422)	363 (280; 413)	376 (300; 436)	NS
EQ-VAS	58 (40; 72)	56 (34; 74)	60 (42; 70)	NS
Laboratory
– NT-proBNP (pg/mL)	1267 (732; 2317)	903 (724; 1979)	1587 (922; 3182)	NS
– Haemoglobin (g/L)	138 (128; 148)	145 (135; 148)	131 (117; 147)	NS
– Creatinine (µmol/L)	94 (80; 113)	95 (81; 112)	94 (73; 114)	NS
Echocardiography
– LV end-diastolic diameter in PLAX (mm)	49 (44; 54)	49 (45; 54)	49 (44; 54)	NS
– LV ejection fraction (%)	60 (55; 63)	60 (55; 62)	60 (56; 64)	NS
– LA indexed volume (mL/m²)	41 (31; 50)	39 (28; 51)	43 (32; 50)	NS
– RA diameter in A4C (mm)	53 (46; 59)	51 (46; 59)	54 (47; 59)	NS
– RV diameter in A4C (mm)	48 (41; 53)	49 (41; 52)	48 (42; 56)	NS
– Tricuspid annular plane systolic excursion (mm)	18 (14; 20)	17 (14; 20)	19 (14; 20)	NS
– Pulmonary artery systolic pressure (mmHg)	69 (50; 84)	72 (55; 87)	64 (48; 82)	NS
– LA appendage emptying velocity (m/s)	0.45 (0.34; 0.70)	0.49 (0.38; 0.70)	0.40 (0.30; 0.70)	NS
Haemodynamics
– RA mean pressure (mmHg)	11 (6; 16)	13 (8; 18)	9 (5; 12)	0.02
– Pulmonary artery mean pressure (mmHg)	46 (38; 55)	47 (38; 54)	45 (36; 55)	NS
– Pulmonary capillary wedge pressure (mmHg)	11 (9; 15)	12 (10; 19)	11 (9; 13)	NS
– Cardiac index (L/min/m²)	2.4 (2.0; 2.9)	2.35 (2.0; 2.8)	2.4 (2.0; 2.9)	NS

All patients

Limited ablation group

Extended ablation group

n = 74

n = 38

n = 36

Age (years)

71 (61; 75)

70 (61; 75)

71 (60; 74)

Males

41 (55%)

24 (63%)

17 (47%)

Aetiology of PH

– Idiopathic

41 (55%)

23 (61%)

18 (50%)

– Chronic thromboembolic

22 (30%)

10 (26%)

12 (33%)

– Lung disease/hypoxia

11 (15%)

5 (13%)

6 (17%)

Index arrhythmia

– Atrial fibrillation

38 (51%)

19 (50%)

19 (53%)

– Paroxysmal

11 (15%)

6 (16%)

5 (14%)

– Persistent

22 (30%)

10 (26%)

12 (33%)

– Long-standing persistent

5 (7%)

3 (8%)

2 (6%)

– Atrial tachycardia

36 (49%)

19 (50%)

17 (47%)

– Typical atrial flutter

23 (31%)

12 (32%)

11 (31%)

Symptoms of arrhythmia

– Palpitation

28 (38%)

13 (34%)

15 (42%)

– Dyspnea

47 (64%)

24 (63%)

23 (64%)

– Peripheral oedema

26 (35%)

12 (32%)

14 (39%)

Comorbidities

– Arterial hypertension

59 (80%)

31 (82%)

28 (78%)

– Diabetes mellitus

26 (35%)

12 (32%)

14 (39%)

– Coronary artery disease

14 (19%)

5 (13%)

9 (25%)

– Stroke/transient ischaemic attack

6 (8%)

4 (11%)

2 (6%)

CHA₂DS₂-VASc score

3 (2; 4)

HAS-BLED score

1 (0; 1)

1 (0.5; 1)

Treatment

– Amiodarone

14 (19%)

8 (21%)

6 (17%)

– Propafenone

3 (4%)

2 (5%)

1 (3%)

– Sotalol

2 (3%)

1 (3%)

– Beta-blockers

27 (36%)

13 (34%)

14 (38%)

– Warfarin

37 (50%)

18 (47%)

19 (53%)

– Direct oral anticoagulants

31 (42%)

18 (47%)

13 (36%)

– Specific therapy for PH

26 (35%)

14 (37%)

12 (33%)

Functional status

– NYHA I

– NYHA II

17 (23%)

9 (24%)

8 (22%)

– NYHA III

57 (77%)

29 (76%)

28 (78%)

– NYHA IV

– 6-minute walking test (m)

369 (280; 422)

363 (280; 413)

376 (300; 436)

EQ-VAS

58 (40; 72)

56 (34; 74)

60 (42; 70)

Laboratory

– NT-proBNP (pg/mL)

1267 (732; 2317)

903 (724; 1979)

1587 (922; 3182)

– Haemoglobin (g/L)

138 (128; 148)

145 (135; 148)

131 (117; 147)

– Creatinine (µmol/L)

94 (80; 113)

95 (81; 112)

94 (73; 114)

Echocardiography

– LV end-diastolic diameter in PLAX (mm)

49 (44; 54)

49 (45; 54)

49 (44; 54)

– LV ejection fraction (%)

60 (55; 63)

60 (55; 62)

60 (56; 64)

– LA indexed volume (mL/m²)

41 (31; 50)

39 (28; 51)

43 (32; 50)

– RA diameter in A4C (mm)

53 (46; 59)

51 (46; 59)

54 (47; 59)

– RV diameter in A4C (mm)

48 (41; 53)

49 (41; 52)

48 (42; 56)

– Tricuspid annular plane systolic excursion (mm)

18 (14; 20)

17 (14; 20)

19 (14; 20)

– Pulmonary artery systolic pressure (mmHg)

69 (50; 84)

72 (55; 87)

64 (48; 82)

– LA appendage emptying velocity (m/s)

0.45 (0.34; 0.70)

0.49 (0.38; 0.70)

0.40 (0.30; 0.70)

Haemodynamics

– RA mean pressure (mmHg)

11 (6; 16)

13 (8; 18)

9 (5; 12)

0.02

– Pulmonary artery mean pressure (mmHg)

46 (38; 55)

47 (38; 54)

45 (36; 55)

– Pulmonary capillary wedge pressure (mmHg)

11 (9; 15)

12 (10; 19)

11 (9; 13)

– Cardiac index (L/min/m²)

2.4 (2.0; 2.9)

2.35 (2.0; 2.8)

2.4 (2.0; 2.9)

	All patients	Limited ablation group	Extended ablation group	P
Age (years)	71 (61; 75)	70 (61; 75)	71 (60; 74)	NS
Males	41 (55%)	24 (63%)	17 (47%)	NS
Aetiology of PH
– Idiopathic	41 (55%)	23 (61%)	18 (50%)	NS
– Chronic thromboembolic	22 (30%)	10 (26%)	12 (33%)	NS
– Lung disease/hypoxia	11 (15%)	5 (13%)	6 (17%)	NS
Index arrhythmia
– Atrial fibrillation	38 (51%)	19 (50%)	19 (53%)	NS
– Paroxysmal	11 (15%)	6 (16%)	5 (14%)	NS
– Persistent	22 (30%)	10 (26%)	12 (33%)	NS
– Long-standing persistent	5 (7%)	3 (8%)	2 (6%)	NS
– Atrial tachycardia	36 (49%)	19 (50%)	17 (47%)	NS
– Typical atrial flutter	23 (31%)	12 (32%)	11 (31%)	NS
Symptoms of arrhythmia
– Palpitation	28 (38%)	13 (34%)	15 (42%)	NS
– Dyspnea	47 (64%)	24 (63%)	23 (64%)	NS
– Peripheral oedema	26 (35%)	12 (32%)	14 (39%)	NS
Comorbidities
– Arterial hypertension	59 (80%)	31 (82%)	28 (78%)	NS
– Diabetes mellitus	26 (35%)	12 (32%)	14 (39%)	NS
– Coronary artery disease	14 (19%)	5 (13%)	9 (25%)	NS
– Stroke/transient ischaemic attack	6 (8%)	4 (11%)	2 (6%)	NS
CHA₂DS₂-VASc score	3 (2; 4)	3 (2; 4)	3 (2; 4)	NS
HAS-BLED score	1 (0; 1)	1 (0; 1)	1 (0.5; 1)	NS
Treatment
– Amiodarone	14 (19%)	8 (21%)	6 (17%)	NS
– Propafenone	3 (4%)	2 (5%)	1 (3%)	NS
– Sotalol	2 (3%)	1 (3%)	1 (3%)	NS
– Beta-blockers	27 (36%)	13 (34%)	14 (38%)	NS
– Warfarin	37 (50%)	18 (47%)	19 (53%)	NS
– Direct oral anticoagulants	31 (42%)	18 (47%)	13 (36%)	NS
– Specific therapy for PH	26 (35%)	14 (37%)	12 (33%)	NS
Functional status
– NYHA I	0	0	0	NS
– NYHA II	17 (23%)	9 (24%)	8 (22%)	NS
– NYHA III	57 (77%)	29 (76%)	28 (78%)	NS
– NYHA IV	0	0	0	NS
– 6-minute walking test (m)	369 (280; 422)	363 (280; 413)	376 (300; 436)	NS
EQ-VAS	58 (40; 72)	56 (34; 74)	60 (42; 70)	NS
Laboratory
– NT-proBNP (pg/mL)	1267 (732; 2317)	903 (724; 1979)	1587 (922; 3182)	NS
– Haemoglobin (g/L)	138 (128; 148)	145 (135; 148)	131 (117; 147)	NS
– Creatinine (µmol/L)	94 (80; 113)	95 (81; 112)	94 (73; 114)	NS
Echocardiography
– LV end-diastolic diameter in PLAX (mm)	49 (44; 54)	49 (45; 54)	49 (44; 54)	NS
– LV ejection fraction (%)	60 (55; 63)	60 (55; 62)	60 (56; 64)	NS
– LA indexed volume (mL/m²)	41 (31; 50)	39 (28; 51)	43 (32; 50)	NS
– RA diameter in A4C (mm)	53 (46; 59)	51 (46; 59)	54 (47; 59)	NS
– RV diameter in A4C (mm)	48 (41; 53)	49 (41; 52)	48 (42; 56)	NS
– Tricuspid annular plane systolic excursion (mm)	18 (14; 20)	17 (14; 20)	19 (14; 20)	NS
– Pulmonary artery systolic pressure (mmHg)	69 (50; 84)	72 (55; 87)	64 (48; 82)	NS
– LA appendage emptying velocity (m/s)	0.45 (0.34; 0.70)	0.49 (0.38; 0.70)	0.40 (0.30; 0.70)	NS
Haemodynamics
– RA mean pressure (mmHg)	11 (6; 16)	13 (8; 18)	9 (5; 12)	0.02
– Pulmonary artery mean pressure (mmHg)	46 (38; 55)	47 (38; 54)	45 (36; 55)	NS
– Pulmonary capillary wedge pressure (mmHg)	11 (9; 15)	12 (10; 19)	11 (9; 13)	NS
– Cardiac index (L/min/m²)	2.4 (2.0; 2.9)	2.35 (2.0; 2.8)	2.4 (2.0; 2.9)	NS

All patients

Limited ablation group

Extended ablation group

n = 74

n = 38

n = 36

Age (years)

71 (61; 75)

70 (61; 75)

71 (60; 74)

Males

41 (55%)

24 (63%)

17 (47%)

Aetiology of PH

– Idiopathic

41 (55%)

23 (61%)

18 (50%)

– Chronic thromboembolic

22 (30%)

10 (26%)

12 (33%)

– Lung disease/hypoxia

11 (15%)

5 (13%)

6 (17%)

Index arrhythmia

– Atrial fibrillation

38 (51%)

19 (50%)

19 (53%)

– Paroxysmal

11 (15%)

6 (16%)

5 (14%)

– Persistent

22 (30%)

10 (26%)

12 (33%)

– Long-standing persistent

5 (7%)

3 (8%)

2 (6%)

– Atrial tachycardia

36 (49%)

19 (50%)

17 (47%)

– Typical atrial flutter

23 (31%)

12 (32%)

11 (31%)

Symptoms of arrhythmia

– Palpitation

28 (38%)

13 (34%)

15 (42%)

– Dyspnea

47 (64%)

24 (63%)

23 (64%)

– Peripheral oedema

26 (35%)

12 (32%)

14 (39%)

Comorbidities

– Arterial hypertension

59 (80%)

31 (82%)

28 (78%)

– Diabetes mellitus

26 (35%)

12 (32%)

14 (39%)

– Coronary artery disease

14 (19%)

5 (13%)

9 (25%)

– Stroke/transient ischaemic attack

6 (8%)

4 (11%)

2 (6%)

CHA₂DS₂-VASc score

3 (2; 4)

HAS-BLED score

1 (0; 1)

1 (0.5; 1)

Treatment

– Amiodarone

14 (19%)

8 (21%)

6 (17%)

– Propafenone

3 (4%)

2 (5%)

1 (3%)

– Sotalol

2 (3%)

1 (3%)

– Beta-blockers

27 (36%)

13 (34%)

14 (38%)

– Warfarin

37 (50%)

18 (47%)

19 (53%)

– Direct oral anticoagulants

31 (42%)

18 (47%)

13 (36%)

– Specific therapy for PH

26 (35%)

14 (37%)

12 (33%)

Functional status

– NYHA I

– NYHA II

17 (23%)

9 (24%)

8 (22%)

– NYHA III

57 (77%)

29 (76%)

28 (78%)

– NYHA IV

– 6-minute walking test (m)

369 (280; 422)

363 (280; 413)

376 (300; 436)

EQ-VAS

58 (40; 72)

56 (34; 74)

60 (42; 70)

Laboratory

– NT-proBNP (pg/mL)

1267 (732; 2317)

903 (724; 1979)

1587 (922; 3182)

– Haemoglobin (g/L)

138 (128; 148)

145 (135; 148)

131 (117; 147)

– Creatinine (µmol/L)

94 (80; 113)

95 (81; 112)

94 (73; 114)

Echocardiography

– LV end-diastolic diameter in PLAX (mm)

49 (44; 54)

49 (45; 54)

49 (44; 54)

– LV ejection fraction (%)

60 (55; 63)

60 (55; 62)

60 (56; 64)

– LA indexed volume (mL/m²)

41 (31; 50)

39 (28; 51)

43 (32; 50)

– RA diameter in A4C (mm)

53 (46; 59)

51 (46; 59)

54 (47; 59)

– RV diameter in A4C (mm)

48 (41; 53)

49 (41; 52)

48 (42; 56)

– Tricuspid annular plane systolic excursion (mm)

18 (14; 20)

17 (14; 20)

19 (14; 20)

– Pulmonary artery systolic pressure (mmHg)

69 (50; 84)

72 (55; 87)

64 (48; 82)

– LA appendage emptying velocity (m/s)

0.45 (0.34; 0.70)

0.49 (0.38; 0.70)

0.40 (0.30; 0.70)

Haemodynamics

– RA mean pressure (mmHg)

11 (6; 16)

13 (8; 18)

9 (5; 12)

0.02

– Pulmonary artery mean pressure (mmHg)

46 (38; 55)

47 (38; 54)

45 (36; 55)

– Pulmonary capillary wedge pressure (mmHg)

11 (9; 15)

12 (10; 19)

11 (9; 13)

– Cardiac index (L/min/m²)

2.4 (2.0; 2.9)

2.35 (2.0; 2.8)

2.4 (2.0; 2.9)

Table 1

Open in new tab

Baseline characteristics

	All patients	Limited ablation group	Extended ablation group	P
	n = 74	n = 38	n = 36	P
Age (years)	71 (61; 75)	70 (61; 75)	71 (60; 74)	NS
Males	41 (55%)	24 (63%)	17 (47%)	NS
Aetiology of PH
– Idiopathic	41 (55%)	23 (61%)	18 (50%)	NS
– Chronic thromboembolic	22 (30%)	10 (26%)	12 (33%)	NS
– Lung disease/hypoxia	11 (15%)	5 (13%)	6 (17%)	NS
Index arrhythmia
– Atrial fibrillation	38 (51%)	19 (50%)	19 (53%)	NS
– Paroxysmal	11 (15%)	6 (16%)	5 (14%)	NS
– Persistent	22 (30%)	10 (26%)	12 (33%)	NS
– Long-standing persistent	5 (7%)	3 (8%)	2 (6%)	NS
– Atrial tachycardia	36 (49%)	19 (50%)	17 (47%)	NS
– Typical atrial flutter	23 (31%)	12 (32%)	11 (31%)	NS
Symptoms of arrhythmia
– Palpitation	28 (38%)	13 (34%)	15 (42%)	NS
– Dyspnea	47 (64%)	24 (63%)	23 (64%)	NS
– Peripheral oedema	26 (35%)	12 (32%)	14 (39%)	NS
Comorbidities
– Arterial hypertension	59 (80%)	31 (82%)	28 (78%)	NS
– Diabetes mellitus	26 (35%)	12 (32%)	14 (39%)	NS
– Coronary artery disease	14 (19%)	5 (13%)	9 (25%)	NS
– Stroke/transient ischaemic attack	6 (8%)	4 (11%)	2 (6%)	NS
CHA₂DS₂-VASc score	3 (2; 4)	3 (2; 4)	3 (2; 4)	NS
HAS-BLED score	1 (0; 1)	1 (0; 1)	1 (0.5; 1)	NS
Treatment
– Amiodarone	14 (19%)	8 (21%)	6 (17%)	NS
– Propafenone	3 (4%)	2 (5%)	1 (3%)	NS
– Sotalol	2 (3%)	1 (3%)	1 (3%)	NS
– Beta-blockers	27 (36%)	13 (34%)	14 (38%)	NS
– Warfarin	37 (50%)	18 (47%)	19 (53%)	NS
– Direct oral anticoagulants	31 (42%)	18 (47%)	13 (36%)	NS
– Specific therapy for PH	26 (35%)	14 (37%)	12 (33%)	NS
Functional status
– NYHA I	0	0	0	NS
– NYHA II	17 (23%)	9 (24%)	8 (22%)	NS
– NYHA III	57 (77%)	29 (76%)	28 (78%)	NS
– NYHA IV	0	0	0	NS
– 6-minute walking test (m)	369 (280; 422)	363 (280; 413)	376 (300; 436)	NS
EQ-VAS	58 (40; 72)	56 (34; 74)	60 (42; 70)	NS
Laboratory
– NT-proBNP (pg/mL)	1267 (732; 2317)	903 (724; 1979)	1587 (922; 3182)	NS
– Haemoglobin (g/L)	138 (128; 148)	145 (135; 148)	131 (117; 147)	NS
– Creatinine (µmol/L)	94 (80; 113)	95 (81; 112)	94 (73; 114)	NS
Echocardiography
– LV end-diastolic diameter in PLAX (mm)	49 (44; 54)	49 (45; 54)	49 (44; 54)	NS
– LV ejection fraction (%)	60 (55; 63)	60 (55; 62)	60 (56; 64)	NS
– LA indexed volume (mL/m²)	41 (31; 50)	39 (28; 51)	43 (32; 50)	NS
– RA diameter in A4C (mm)	53 (46; 59)	51 (46; 59)	54 (47; 59)	NS
– RV diameter in A4C (mm)	48 (41; 53)	49 (41; 52)	48 (42; 56)	NS
– Tricuspid annular plane systolic excursion (mm)	18 (14; 20)	17 (14; 20)	19 (14; 20)	NS
– Pulmonary artery systolic pressure (mmHg)	69 (50; 84)	72 (55; 87)	64 (48; 82)	NS
– LA appendage emptying velocity (m/s)	0.45 (0.34; 0.70)	0.49 (0.38; 0.70)	0.40 (0.30; 0.70)	NS
Haemodynamics
– RA mean pressure (mmHg)	11 (6; 16)	13 (8; 18)	9 (5; 12)	0.02
– Pulmonary artery mean pressure (mmHg)	46 (38; 55)	47 (38; 54)	45 (36; 55)	NS
– Pulmonary capillary wedge pressure (mmHg)	11 (9; 15)	12 (10; 19)	11 (9; 13)	NS
– Cardiac index (L/min/m²)	2.4 (2.0; 2.9)	2.35 (2.0; 2.8)	2.4 (2.0; 2.9)	NS

	All patients	Limited ablation group	Extended ablation group	P
	n = 74	n = 38	n = 36	P
Age (years)	71 (61; 75)	70 (61; 75)	71 (60; 74)	NS
Males	41 (55%)	24 (63%)	17 (47%)	NS
Aetiology of PH
– Idiopathic	41 (55%)	23 (61%)	18 (50%)	NS
– Chronic thromboembolic	22 (30%)	10 (26%)	12 (33%)	NS
– Lung disease/hypoxia	11 (15%)	5 (13%)	6 (17%)	NS
Index arrhythmia
– Atrial fibrillation	38 (51%)	19 (50%)	19 (53%)	NS
– Paroxysmal	11 (15%)	6 (16%)	5 (14%)	NS
– Persistent	22 (30%)	10 (26%)	12 (33%)	NS
– Long-standing persistent	5 (7%)	3 (8%)	2 (6%)	NS
– Atrial tachycardia	36 (49%)	19 (50%)	17 (47%)	NS
– Typical atrial flutter	23 (31%)	12 (32%)	11 (31%)	NS
Symptoms of arrhythmia
– Palpitation	28 (38%)	13 (34%)	15 (42%)	NS
– Dyspnea	47 (64%)	24 (63%)	23 (64%)	NS
– Peripheral oedema	26 (35%)	12 (32%)	14 (39%)	NS
Comorbidities
– Arterial hypertension	59 (80%)	31 (82%)	28 (78%)	NS
– Diabetes mellitus	26 (35%)	12 (32%)	14 (39%)	NS
– Coronary artery disease	14 (19%)	5 (13%)	9 (25%)	NS
– Stroke/transient ischaemic attack	6 (8%)	4 (11%)	2 (6%)	NS
CHA₂DS₂-VASc score	3 (2; 4)	3 (2; 4)	3 (2; 4)	NS
HAS-BLED score	1 (0; 1)	1 (0; 1)	1 (0.5; 1)	NS
Treatment
– Amiodarone	14 (19%)	8 (21%)	6 (17%)	NS
– Propafenone	3 (4%)	2 (5%)	1 (3%)	NS
– Sotalol	2 (3%)	1 (3%)	1 (3%)	NS
– Beta-blockers	27 (36%)	13 (34%)	14 (38%)	NS
– Warfarin	37 (50%)	18 (47%)	19 (53%)	NS
– Direct oral anticoagulants	31 (42%)	18 (47%)	13 (36%)	NS
– Specific therapy for PH	26 (35%)	14 (37%)	12 (33%)	NS
Functional status
– NYHA I	0	0	0	NS
– NYHA II	17 (23%)	9 (24%)	8 (22%)	NS
– NYHA III	57 (77%)	29 (76%)	28 (78%)	NS
– NYHA IV	0	0	0	NS
– 6-minute walking test (m)	369 (280; 422)	363 (280; 413)	376 (300; 436)	NS
EQ-VAS	58 (40; 72)	56 (34; 74)	60 (42; 70)	NS
Laboratory
– NT-proBNP (pg/mL)	1267 (732; 2317)	903 (724; 1979)	1587 (922; 3182)	NS
– Haemoglobin (g/L)	138 (128; 148)	145 (135; 148)	131 (117; 147)	NS
– Creatinine (µmol/L)	94 (80; 113)	95 (81; 112)	94 (73; 114)	NS
Echocardiography
– LV end-diastolic diameter in PLAX (mm)	49 (44; 54)	49 (45; 54)	49 (44; 54)	NS
– LV ejection fraction (%)	60 (55; 63)	60 (55; 62)	60 (56; 64)	NS
– LA indexed volume (mL/m²)	41 (31; 50)	39 (28; 51)	43 (32; 50)	NS
– RA diameter in A4C (mm)	53 (46; 59)	51 (46; 59)	54 (47; 59)	NS
– RV diameter in A4C (mm)	48 (41; 53)	49 (41; 52)	48 (42; 56)	NS
– Tricuspid annular plane systolic excursion (mm)	18 (14; 20)	17 (14; 20)	19 (14; 20)	NS
– Pulmonary artery systolic pressure (mmHg)	69 (50; 84)	72 (55; 87)	64 (48; 82)	NS
– LA appendage emptying velocity (m/s)	0.45 (0.34; 0.70)	0.49 (0.38; 0.70)	0.40 (0.30; 0.70)	NS
Haemodynamics
– RA mean pressure (mmHg)	11 (6; 16)	13 (8; 18)	9 (5; 12)	0.02
– Pulmonary artery mean pressure (mmHg)	46 (38; 55)	47 (38; 54)	45 (36; 55)	NS
– Pulmonary capillary wedge pressure (mmHg)	11 (9; 15)	12 (10; 19)	11 (9; 13)	NS
– Cardiac index (L/min/m²)	2.4 (2.0; 2.9)	2.35 (2.0; 2.8)	2.4 (2.0; 2.9)	NS

Data represent the number of cases (percentage) or median (interquartile range).

A4C, apical four-chamber view; EQ-VAS, European Quality of Life Group instrument self-report questionnaire visual analogue scale; NS, not significant; LA, left atrium; LV, left ventricle; PH, pulmonary hypertension; PLAX, parasternal long axis view; RA, right atrium; RV, right ventricle.

This Feature Is Available To Subscribers Only